PRQR NASDAQ
ProQR Therapeutics N.V.
1W: -0.6%
1M: -23.7%
3M: -4.7%
YTD: -17.6%
1Y: -24.1%
3Y: +18.8%
5Y: -79.0%
$1.64
+0.01 (+0.31%)
Weekly Expected Move ±6.4%
$1
$2
$2
$2
$2
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Cash Flow Trends
Operating Cash Flow
-$51M
-39.3% ▼
Capital Expenditures
$980K
+30.9% ▲
5Y CAGR: +1.2%
Free Cash Flow
-$52M
-36.7% ▼
Dividends Paid
$0
+0.0% ▲
Buybacks
$0
+0.0% ▲
Net Change in Cash
-$39M
-228.9% ▼
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | -$61M | -$64M | -$28M | -$28M | -$41M |
| Depreciation & Amort. | $2M | $3M | $3M | $3M | $3M |
| Stock-Based Comp. | $6M | $3M | $3M | $3M | $0 |
| Change in Working Capital | $25M | -$5M | $49M | -$13M | -$17M |
| Other Non-Cash Items | $1M | -$5M | -$5M | -$474K | $4M |
| Operating Cash Flow | -$26M | -$69M | $22M | -$36M | -$51M |
| — Investing Activities — | |||||
| Capital Expenditures | -$484K | -$708K | -$1M | -$1M | -$980K |
| Acquisitions (Net) | $0 | $0 | $0 | $0 | $0 |
| Investment Purchases | $0 | $0 | $0 | -$17M | $0 |
| Investment Sales | $0 | $0 | $0 | $17M | $0 |
| Other Investing | $59K | $6K | $6M | -$3M | $0 |
| Investing Cash Flow | -$425K | -$702K | $4M | -$4M | -$980K |
| — Financing Activities — | |||||
| Net Debt Issuance | $27M | -$45M | -$3M | -$2M | -$2M |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 |
| Other Financing | $2M | $34K | $354K | $223K | $75K |
| Financing Cash Flow | $137M | -$31M | -$2M | $70M | -$2M |
| Net Change in Cash | $112M | -$93M | $24M | $30M | -$39M |
| Cash End of Period | $188M | $95M | $119M | $149M | $92M |
| Free Cash Flow | -$26M | -$69M | $20M | -$38M | -$52M |